San Francisco Business Times: Risky Downside to California's $75 Million Stem Cell Venture Plan
The stem cell agency plan is dubbed ATP3. Here is some of the criteria.
California’s $75 million, stem-cell dip into venture capital waters poses an “embarrassing risk,” according to a story in the San Francisco Business Times.
The article by by Ron Leuty said,
“The strategy offers a potential high return for CIRM and the stem cell field in general, and i…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.